Pancreatic Cancer Research

ResearcherUniversity of MinnesotaActive in the last 2 years

Zoe C. Schmiechen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3403-6824; OpenAlex author ID A5029748302; NIH RePORTER profile ID 15325231. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
13
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 grant · 2025: 2 papers · 2026: 2 papers

Papers 8

  1. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Co-author DOI 10.1126/sciimmunol.adz4302↗
  2. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2-deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2026-015489↗
  3. IL-15 complex enhances therapeutic efficacy of anti-PD-L1 in a T cell-dependent and NK cell-independent manner in a murine model of pancreatic ductal adenocarc… Co-author DOI 10.1093/jimmun/vkaf314↗
  4. IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-24-0758↗
  5. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2023.112732↗
  6. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer. First author DOI 10.1172/jci.insight.151593↗
  7. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. Co-author DOI 10.4049/jimmunol.2000765↗
  8. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2020.613815↗

Grants 1

  1. Elucidating the Role of Tregs in Cancer Metastasis and T Cell Dysfunction F31CA275289↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingunn M. Stromnes · 8 shared papers, 2020–2026 · strength 1.60
  2. Adam L. Burrack · 7 shared papers, 2021–2026 · strength 1.36
  3. Alexander K. Tsai · 4 shared papers, 2025–2026 · strength 0.92
  4. Grant H. Hickok · 4 shared papers, 2023–2026 · strength 0.80
  5. Cara-lin Lonetree · 2 shared papers, 2025–2026 · strength 0.41
  6. Michael T. Patterson · 2 shared papers, 2022–2023 · strength 0.30
  7. David Masopust · 1 shared paper, 2026 · strength 0.23
  8. Paolo Provenzano · 1 shared paper, 2026 · strength 0.23
  9. Guhan Qian · 1 shared paper, 2026 · strength 0.23
  10. Philip D. Greenberg · 1 shared paper, 2026 · strength 0.23
  11. Sunil R. Hingorani · 1 shared paper, 2026 · strength 0.23
  12. Liang‐I Kang · 1 shared paper, 2026 · strength 0.22
  13. David G DeNardo · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.